...Quell Therapeutics Ltd. hired Nathalie Belmonte as SVP, research and translation. She was COO of Promethera Biosciences S.A....

...of majority-owned BioSig subsidiary NeuroClear Technologies Inc., which is developing an antiviral therapy for COVID-19. Promethera Biosciences S.A....
...Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Redpin Therapeutics Inc. Relmada Therapeutics Inc. Assembly Biosciences Inc. BrainStorm Cell Therapeutics Inc. Promethera Biosciences S.A. Cybrexa...

...involves regenerative medicine approaches. For example, the fund is invested in liver cell therapy play Promethera Biosciences S.A....

...and 3. Interim data are expected in 1H20. First patient dosed in Promethera NASH study Promethera Biosciences S.A....
...cells. The trial is slated to be completed in 1H20 (see "Liver Cell Therapy Company Promethera...
...#), nivolumab (Generic), Opdivo (Other) PCV-15 (V114) Promethera HepaStem (HepaStem) SRK-015 Cel-Sci Corp. Great Ormond Street Hospital Merck & Co. Inc. Polyphor Ltd. Promethera Biosciences S.A. Scholar...

...Belgian company Promethera added new Japanese and Korean investors in its series D round Monday, as...
...growing its Asia network to leverage the "openness" to stem cell therapies in the region. Promethera Biosciences S.A....
...readily differentiates into hepatocytes. Tchelingerian declined to give development timelines. Elizabeth S. Eaton, Staff Writer Atrosimab H2Stem Promethera HepaStem (HepaStem) Promethera Biosciences S.A. Tumor...

...of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver failure (ACLF). Promethera Biosciences S.A....
...with ACLF or who had acute decompensation and were at high risk of developing ACLF. Promethera...
...restoring liver function and decreasing mortality and the need for transplantation. Brian Moy, Assistant Editor Promethera HepaStem (HepaStem) Promethera Biosciences S.A. Liver...

...hired Stanley Lewis as CMO. He was CMO of TaiMed Biologics Inc. (TPEx:4147). Hepatic company Promethera Biosciences S.A....

...4/30/18 $141 $75 $216 Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Wilson Therapeutics AB 4/11/18 $848 NA $848 Promethera Biosciences S.A....

...when he joined Promethera as CEO in 2015 was to grow the company’s Asian network. Promethera...
...LifeLiver Co. Ltd., which entered a licensing deal with Promethera in 2017. And in April, Promethera...
...mouse studies, Promethera showed the cells could repopulate damaged livers with mature hepatocytes. Sokal said Promethera...

...said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera...
...of convertible bonds to new investors Shibuya Corp. and Shinsei Group and undisclosed existing investors. Promethera...
...to treat acute-on-chronic liver failure. Baliopharm AG, Basel, Switzerland Promethera Biosciences S.A., Mont-Saint-Guibert, Belgium Business: Hepatic Sandi Wong Baliopharm AG Promethera Biosciences S.A. Tumor...